160 related articles for article (PubMed ID: 37882056)
61. 18F-FDG PET/CT oncologic imaging at extended injection-to-scan acquisition time intervals derived from a single-institution 18F-FDG-directed surgery experience: feasibility and quantification of 18F-FDG accumulation within 18F-FDG-avid lesions and background tissues.
Povoski SP; Murrey DA; Smith SM; Martin EW; Hall NC
BMC Cancer; 2014 Jun; 14():453. PubMed ID: 24942656
[TBL] [Abstract][Full Text] [Related]
62. Difficulty in Distinguishing Pulmonary Arterial Intimal Sarcoma from Pulmonary Thromboembolism Using FDG PET/CT.
Suto H; Suto M; Inui Y; Okamura A
In Vivo; 2022; 36(3):1519-1522. PubMed ID: 35478156
[TBL] [Abstract][Full Text] [Related]
63. Delayed Diagnosis of SMARCA4-Deficient Undifferentiated Tumor in a Heavy Smoker Male Patient: Discovered Through Bone Sampling, with Extensive Distant Metastases and Concurrent Granulomatous Disease, Leading to Patient Fatality.
Shaker N; Ben Musa R; Tynski Z; Shaker N; Sangueza OP; Boyd B
Int J Surg Pathol; 2024 Jun; ():10668969241260215. PubMed ID: 38899907
[No Abstract] [Full Text] [Related]
64. 68 Ga-FAPI Versus 18 F-FDG PET/CT in Recurrent Undifferentiated Pleomorphic Sarcoma of Colon Mesentery.
Zhang L; Liu Z; Jiang S; He Q; Zhang R
Clin Nucl Med; 2022 Oct; 47(10):e651-e653. PubMed ID: 35605050
[TBL] [Abstract][Full Text] [Related]
65. FDG PET/CT in Eosinophilic Solid and Cystic Renal Cell Carcinoma With Lung Metastases.
Zhang J; Dong A; Wang Y
Clin Nucl Med; 2022 Oct; 47(10):921-922. PubMed ID: 35605053
[TBL] [Abstract][Full Text] [Related]
66. Clinical implications of 18F-fluorodeoxyglucose positron emission tomography/computed tomography at delayed phase for diagnosis and prognosis of malignant pleural mesothelioma.
Abe Y; Tamura K; Sakata I; Ishida J; Ozeki Y; Tamura A; Uematsu K; Sakai H; Goya T; Kanazawa M; Machida K
Oncol Rep; 2012 Feb; 27(2):333-8. PubMed ID: 22024889
[TBL] [Abstract][Full Text] [Related]
67. 68 Ga-FAPI PET/CT Detection of Non-FDG-Avid Poorly Differentiated Adenocarcinoma of the Trachea.
Ding H; Guo C; Liang J; Liu Y; Chen Y
Clin Nucl Med; 2023 Jul; 48(7):615-616. PubMed ID: 37167102
[TBL] [Abstract][Full Text] [Related]
68. Potential of dual time point FDG-PET imaging in differentiating malignant from benign pleural disease.
Mavi A; Basu S; Cermik TF; Urhan M; Bathaii M; Thiruvenkatasamy D; Houseni M; Dadparvar S; Alavi A
Mol Imaging Biol; 2009; 11(5):369-78. PubMed ID: 19472014
[TBL] [Abstract][Full Text] [Related]
69. FDG PET/CT Image of Soft Tissue Aneurysmal Bone Cyst.
Xiao L; Cheng J; Li L
Clin Nucl Med; 2022 Oct; 47(10):e632-e634. PubMed ID: 35426845
[TBL] [Abstract][Full Text] [Related]
70. FDG PET/CT in a Case With Primary Poorly Differentiated Urothelial-Type Adenocarcinoma of the Prostate.
Dong A; Zhu Y; Zuo C
Clin Nucl Med; 2022 Aug; 47(8):736-738. PubMed ID: 35797631
[TBL] [Abstract][Full Text] [Related]
71. The value of SOX2 in the differential diagnosis of SMARCA4 (BRG1)-deficient uterine neoplasms.
Zheng L; Zhang L; Wang XI; Katz G; Tandon N; Zhao B; Lucci J; Ding J; Zhang S
Hum Pathol; 2022 Jun; 124():45-55. PubMed ID: 35331811
[TBL] [Abstract][Full Text] [Related]
72. An assessment of
So A; Pointon O; Hodgson R; Burgess J
Clin Endocrinol (Oxf); 2018 May; 88(5):683-691. PubMed ID: 29446832
[TBL] [Abstract][Full Text] [Related]
73. Thoracic SMARCA4-Deficient Undifferentiated Tumor Mimicking a Pleural Mesothelioma on 18F-FDG PET/CT.
Chen X; Chen G; Li Q; Fu Z
Clin Nucl Med; 2024 May; ():. PubMed ID: 38768095
[TBL] [Abstract][Full Text] [Related]
74. Metastatic undifferentiated spindle cell sarcoma of the thyroid gland evaluated by 18F-FDG PET/CT.
Treglia G; Bongiovanni M; Paone G; Ceriani L; Giovanella L
Clin Nucl Med; 2015 Mar; 40(3):e208-10. PubMed ID: 25140545
[TBL] [Abstract][Full Text] [Related]
75. Significance of incidental intra-articular and peri-articular FDG avid foci on PET/CT.
Cohen-Levy WB; Pretell-Mazzini J; Singer AD; Subhawong T; Greif DN; Jose J
Acta Radiol; 2019 Jan; 60(1):78-84. PubMed ID: 29665710
[TBL] [Abstract][Full Text] [Related]
76. [Clinical characteristics and prognosis analysis of 17 cases of SMARCA4-deficient chest tumors].
Cao XN; Li Z; Wang QY
Zhonghua Jie He He Hu Xi Za Zhi; 2024 Apr; 47(4):325-331. PubMed ID: 38599807
[No Abstract] [Full Text] [Related]
77. Atezolizumab with bevacizumab, paclitaxel and carboplatin was effective for patients with SMARCA4-deficient thoracic sarcoma.
Kawachi H; Kunimasa K; Kukita Y; Nakamura H; Honma K; Kawamura T; Inoue T; Tamiya M; Kuhara H; Nishino K; Mizote Y; Akazawa T; Tahara H; Kumagai T
Immunotherapy; 2021 Jul; 13(10):799-806. PubMed ID: 34030451
[TBL] [Abstract][Full Text] [Related]
78. SMARCA4-deficient non-small cell lung carcinoma: clinicodemographic, computed tomography, and positron emission tomography-computed tomography features.
Kim JH; Woo JH; Lim CY; An T; Han J; Chung MJ; Cha YK
J Thorac Dis; 2024 Mar; 16(3):1753-1764. PubMed ID: 38617754
[TBL] [Abstract][Full Text] [Related]
79. Diagnostic Ability of FDG-PET/CT in the Detection of Malignant Pleural Effusion.
Nakajima R; Abe K; Sakai S
Medicine (Baltimore); 2015 Jul; 94(29):e1010. PubMed ID: 26200610
[TBL] [Abstract][Full Text] [Related]
80. Indeterminate pleural metastasis on contrast-enhanced chest CT in non-small cell lung cancer: improved differential diagnosis with (18)F-FDG PET/CT.
Jung MY; Chong A; Seon HJ; Choi S; Kim YH; Shin SS; Kim JW; Bom HS
Ann Nucl Med; 2012 May; 26(4):327-36. PubMed ID: 22350956
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
